FYB206
Phase 3Biologic
FYB206 is one of 59 biologic programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.
2
Indications
2
Total Trials
1
Active Trials
58
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1639 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1FYB206
FFormycon AG
Phase 3
Vizimpro
PfizerPreclinical
Immunotherapy
Bristol-Myers SquibbPreclinical
Remeron
OOrganon and Co
Preclinical
Tyrosine Kinase Inhibitor
PfizerPreclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Treatment
GSKPreclinical
Vidaza
Bristol-Myers SquibbPreclinical
REGN2810
RegeneronPreclinical
Huaier Granule
QQidong Gaitianli Medicines Co., Ltd
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for FYB206. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- FFormycon AG